
Amgen Inc.
AMGNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 4, 2026 | Cantor Fitzgerald | Carter Gould | $465.00(-2%) | $473.82 | StreetInsider |
| Nov 4, 2026 | Bernstein | Courtney Breen | $400.00(-15%) | $473.04 | StreetInsider |
| Nov 4, 2026 | RBC Capital | Luca Issi | $470.00(-1%) | $472.82 | StreetInsider |
| Nov 4, 2026 | Truist Financial | Greg Renza | $398.00(-15%) | $469.85 | StreetInsider |
| Nov 4, 2026 | Canaccord Genuity | Gary Nachman | $440.00(-5%) | $461.26 | StreetInsider |
| Nov 4, 2026 | Wells Fargo | Mohit Bansal | $460.00(-0%) | $461.26 | StreetInsider |
| Oct 23, 2026 | Oppenheimer | $480.00(+7%) | $447.28 | StreetInsider | |
| Oct 21, 2026 | Barclays | $400.00(-9%) | $438.94 | TheFly | |
| Oct 13, 2026 | Guggenheim | Vamil Divan | $378.00(-9%) | $417.57 | TheFly |
| Oct 12, 2026 | BMO Capital | $415.00(-0%) | $415.80 | TheFly | |
| Oct 12, 2026 | Wells Fargo | $430.00(+4%) | $414.87 | TheFly | |
| Oct 8, 2026 | RBC Capital | $430.00(+6%) | $407.57 | TheFly | |
| Oct 8, 2026 | Cantor Fitzgerald | Carter Gould | $440.00(+7%) | $413.08 | StreetInsider |
| Oct 7, 2026 | Truist Financial | $380.00(-8%) | $413.67 | TheFly | |
| Sep 28, 2026 | Scotiabank | Louise Chen | $500.00(+20%) | $417.71 | TheFly |
| Sep 23, 2026 | Jefferies | Akash Tewari | $410.00(-0%) | $410.24 | StreetInsider |
| Sep 17, 2026 | UBS | Michael Yee | $430.00(+14%) | $378.42 | StreetInsider |
| Sep 4, 2026 | Wells Fargo | Mohit Bansal | $435.00(-2%) | $444.12 | StreetInsider |
| Aug 20, 2026 | Piper Sandler | David Amsellem | $457.00(+3%) | $442.36 | TheFly |
| Aug 19, 2026 | Morgan Stanley | $362.00(-18%) | $440.28 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Freedom Broker | downgrade | Buy →Hold | Nov 6, 2026 |
| Guggenheim | maintain | Neutral | Nov 5, 2026 |
| Leerink Partners | maintain | Market Perform | Nov 5, 2026 |
| UBS | maintain | Buy | Nov 4, 2026 |
| Goldman Sachs | maintain | Buy | Nov 4, 2026 |
| TD Cowen | maintain | Buy | Nov 4, 2026 |
| JP Morgan | maintain | Neutral | Nov 4, 2026 |
| Citigroup | maintain | Neutral | Nov 4, 2026 |
| Canaccord Genuity | maintain | Hold | Nov 4, 2026 |
| Scotiabank | maintain | Sector Outperform | Nov 4, 2026 |
| Bernstein | maintain | Market Perform | Nov 4, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Nov 4, 2026 |
| Wells Fargo | maintain | Equal Weight | Nov 4, 2026 |
| Truist Securities | maintain | Hold | Nov 4, 2026 |
| RBC Capital | maintain | Outperform | Nov 4, 2026 |
| Morgan Stanley | maintain | Equal Weight | Nov 4, 2026 |
| Oppenheimer | maintain | Outperform | Oct 23, 2026 |
| Barclays | maintain | Equal Weight | Oct 21, 2026 |
| Guggenheim | maintain | Neutral | Oct 13, 2026 |
| BMO Capital | maintain | Market Perform | Oct 12, 2026 |
| Wells Fargo | maintain | Equal Weight | Oct 12, 2026 |
| UBS | maintain | Buy | Oct 9, 2026 |
| RBC Capital | maintain | Outperform | Oct 8, 2026 |
| Cantor Fitzgerald | maintain | Neutral | Oct 8, 2026 |
| Morgan Stanley | maintain | Equal Weight | Oct 7, 2026 |
Earnings History
Next report: Feb 2, 2027 · EPS est. $5.65| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 3, 2026 | $6.45 | $5.79 | $10.37B | $10.07B |
| Aug 4, 2026 | $6.29 | $5.62 | $10.05B | $9.43B |
| Apr 30, 2026 | $5.15 | $4.77 | $8.62B | $8.58B |
| Feb 3, 2026 | $5.29 | $4.73 | $9.87B | $9.47B |
| Nov 4, 2025 | $5.64 | $5.02 | $9.56B | $8.97B |
| Aug 5, 2025 | $6.02 | $5.28 | $9.17B | $8.94B |
| May 1, 2025 | $4.90 | $4.27 | $8.15B | $8.06B |
| Feb 4, 2025 | $5.31 | $5.04 | $9.09B | $8.88B |
News
These are among the best the industry has to offer.
Amgen has raised its payout every year since 2011, yet the pace of those raises is cooling just as patent cliffs and drug price controls close in. One number shows whether the next raise, due soon, will hold up.
Alta Advisers Ltd lifted its stake in shares of Amgen Inc. (NASDAQ: AMGN) by 85.7% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,919 shares of the medical research company's stock after acquiring an additional 1,809 shares during the
Boston Trust Walden Corp trimmed its holdings in Amgen Inc. (NASDAQ: AMGN) by 18.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,134 shares of the medical research company's stock after selling 15,695 shares during the period.
Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance sheet with a lower valuation profile.
Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe Study Examined More Than Half a Million Adults Living with Heart Disease Results Provide Important New Clinical Evidence to Inform Non-Statin Treatment Decisions for Patients THOUSAND OAKS, Calif., Nov. 5, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfa…
AIA Group Ltd cut its holdings in Amgen Inc. (NASDAQ: AMGN) by 25.8% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 15,607 shares of the medical research company's stock after selling 5,422 shares during the period. AIA Group Ltd's holdings in Amgen were worth
First Nebraska Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,369 shares of the medical research company's stock, valued at approximately $999,000. Other institutional
/PRNewswire/ -- Stock Preachers News Commentary - Wall Street roared higher this week, with the Dow jumping 2.87% in a single session to a record 53,275.11 and
Amgen Inc. (NASDAQ:AMGN) shares are trading close to its 52-week high on Wednesday after the company reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance.
Amgen raises its 2026 outlook after Q3 earnings and revenue beat estimates, as IMDELLTRA advances and MariTide offers potential long-term growth opportunities.
Amgen shares fall despite Q3 earnings and revenue beats. Steep declines in Prolia and Xgeva offset strong growth across key drug portfolios and raised 2026 guidance.
Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript
Amgen NASDAQ: AMGN reported third-quarter revenue growth of 8% year over year to $10.4 billion, supported by broad-based demand across its portfolio and continued clinical progress in several late-stage programs. The company raised its full-year revenue and adjusted earnings outlook while highlighting growth in cardiovascular, bone health, inflammation, rare disease, oncology and biosimilar medicines.
Although the revenue and EPS for Amgen (AMGN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amgen (AMGN) came out with quarterly earnings of $6.45 per share, beating the Zacks Consensus Estimate of $5.74 per share. This compares to earnings of $5.64 per share a year ago.
THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.
AMGN, PFE, MRNA, NVO and VTRS are set to report this week as recent beats and key drug demand set up a pivotal Q3 earnings test for pharma giants.
Amgen's cancer drug Imdelltra has been shown to be effective in treating advanced lung cancer when paired with AstraZeneca's Imfinzi. The risk of death was cut by 58% for patients who used the combination treatment.
Collecting four figures a month from dividends without ever selling a share sounds straightforward until you price out what it actually costs and see which companies are holding the whole structure together.